BR112018067613A2 - composição farmacêutica anti-abuso - Google Patents

composição farmacêutica anti-abuso

Info

Publication number
BR112018067613A2
BR112018067613A2 BR112018067613-6A BR112018067613A BR112018067613A2 BR 112018067613 A2 BR112018067613 A2 BR 112018067613A2 BR 112018067613 A BR112018067613 A BR 112018067613A BR 112018067613 A2 BR112018067613 A2 BR 112018067613A2
Authority
BR
Brazil
Prior art keywords
enzyme
drug
pharmaceutical composition
functional group
abuse
Prior art date
Application number
BR112018067613-6A
Other languages
English (en)
Inventor
Gübitz Georg
Greimel Katrin
Brandauer Martin
Huber Daniela
Bleymaier Klaus
Kroutil Wolfgang
Lechner Doris
Wachter Christof
Wagner Harald
Winkler Heimo
Original Assignee
G.L. PHARMA GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G.L. PHARMA GmbH filed Critical G.L. PHARMA GmbH
Publication of BR112018067613A2 publication Critical patent/BR112018067613A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

é divulgada uma composição farmacêutica anti-abuso compreendendo um fármaco com um grupo funcional reativo com enzima, em que o fármaco tem um potencial de abuso e uma enzima capaz de reagir com o grupo funcional reativo com enzima (uma enzima de processamento de fármaco), em que o fármaco com o grupo funcional reativo com enzima está contido na composição farmacêutica num estado reativo com a enzima, estável em armazenamento e sob condições em que nenhuma atividade enzimática atua sobre o fármaco.
BR112018067613-6A 2016-02-29 2017-02-28 composição farmacêutica anti-abuso BR112018067613A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16157798.6A EP3210596A1 (en) 2016-02-29 2016-02-29 Abuse-deterrent pharmaceutical composition
EP16157798.6 2016-02-29
PCT/EP2017/054614 WO2017148927A1 (en) 2016-02-29 2017-02-28 Abuse-deterrent pharmaceutical composition

Publications (1)

Publication Number Publication Date
BR112018067613A2 true BR112018067613A2 (pt) 2019-04-09

Family

ID=55446691

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067613-6A BR112018067613A2 (pt) 2016-02-29 2017-02-28 composição farmacêutica anti-abuso

Country Status (11)

Country Link
US (1) US11077196B2 (pt)
EP (3) EP3210596A1 (pt)
JP (1) JP2019507173A (pt)
CN (1) CN109069419A (pt)
AU (1) AU2017226880A1 (pt)
BR (1) BR112018067613A2 (pt)
CA (1) CA3016578A1 (pt)
CL (1) CL2018002463A1 (pt)
ES (1) ES2745579T3 (pt)
MX (1) MX2018010436A (pt)
WO (1) WO2017148927A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3231420A1 (en) * 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
CN111269901B (zh) * 2020-02-18 2021-08-24 浙江科技学院 一种环氧化物水解酶突变体及其应用
WO2023225630A2 (en) * 2022-05-19 2023-11-23 Virginia Commonwealth University FORMULATIONS FOR ADMINISTERING LAAM, norLAAM AND dinorLAAM AND METHODS OF THEIR USE TO TREAT OPIOID USE DISORDER

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852157A (en) * 1971-05-14 1974-12-03 Syva Corp Compounds for enzyme amplification assay
US4299916A (en) 1979-12-26 1981-11-10 Syva Company Preferential signal production on a surface in immunoassays
US4391904A (en) * 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
JPH02238885A (ja) 1989-03-13 1990-09-21 Oji Paper Co Ltd フェノールオキシダーゼ遺伝子組換えｄｎａ、該組換えｄｎａにより形質転換された微生物、その培養物及びフェノールオキシダーゼの製造方法
FI903443A (fi) 1990-07-06 1992-01-07 Valtion Teknillinen Framstaellning av lackas genom rekombinantorganismer.
NZ242074A (en) 1991-03-22 1993-08-26 Novo Nordisk As Extracellular production of a heterologous heme protein in a filamentous fungus; dna construct therefor
DK77393D0 (da) 1993-06-29 1993-06-29 Novo Nordisk As Aktivering af enzymer
BR9509046A (pt) 1994-09-27 1998-07-14 Novo Nordisk As Processo para oxidar um composto com uma enzima oxidante de fenol e aditivo e composição detergente
JPH11503465A (ja) 1996-01-31 1999-03-26 ギスト ブロカデス ベスローテン フェンノートシャップ 安定化された生物学的に有効な化合物を含む組成物の使用
DE69737828T2 (de) 1996-04-29 2008-03-06 Novozymes A/S Flüssige, nichtwässrige enzyme enthaltende zusammensetzungen
JP3320307B2 (ja) 1996-06-06 2002-09-03 株式会社エス・ディー・エス バイオテック フェノール性化合物等の高分子化方法及びその利用
GB9622516D0 (en) 1996-10-29 1997-01-08 Univ Cambridge Tech Enzymic cofactor cycling
CA2316249C (en) 1998-07-08 2012-11-27 Novo Nordisk A/S Use of a phenol oxidising enzyme in the treatment of tobacco
BR9915155B1 (pt) 1998-11-09 2012-03-06 mÉtodos para matar ou inibir cÉlulas microbianas, para inibir microorganismos presentes na lavanderia, para preservar um produto cosmÉtico e para limpar, desinfetar ou inibir o desenvolvimento microbiano em uma superfÍcie dura, composiÇÕes detergente e enzimÁtica antimicrobiana, e, uso de uma composiÇço.
DE10029671A1 (de) 2000-06-23 2002-01-10 Frieder Schauer Biotransformation von biologisch aktiven Verindungen aus verschiedenen chemischen Stoffklassen mittels der Enzyme Laccase und Manganperoxidase
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
JP2007525146A (ja) 2003-12-30 2007-09-06 ガムリンク エー／エス 生分解性ポリマーを含み且つ分解性を促進させたチューインガム
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
AU2012201450A1 (en) * 2004-11-24 2012-04-05 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
WO2006133733A1 (en) * 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
EP2028951B1 (en) 2006-06-16 2011-04-27 Gumlink A/S Chewing gum comprising a hydrophobic enzyme formulation
DK2526932T3 (en) 2006-06-19 2017-07-17 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2068840A2 (en) 2006-07-21 2009-06-17 LAB International SRL Hydrophobic abuse deterrent delivery system
DE102006048833A1 (de) 2006-10-16 2008-04-17 Universität Rostock Behandlung von Osteoporose
WO2008068471A1 (en) * 2006-12-04 2008-06-12 Orexo Ab New non-abusable pharmaceutical composition comprising opioids
NZ594513A (en) * 2009-03-04 2013-10-25 Orexo Ab Abuse resistant formulation
US20110262359A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
JP5759544B2 (ja) 2010-07-02 2015-08-05 ザ プロクター アンド ギャンブルカンパニー 活性剤を送達する方法
WO2012061779A1 (en) 2010-11-04 2012-05-10 Abbott Gmbh & Co. Kg Drug formulations
WO2012085016A1 (de) 2010-12-20 2012-06-28 Cytec Austria Gmbh Verfahren zur härtung von oberflächenbeschichtungsmitteln
US8497237B2 (en) * 2011-01-11 2013-07-30 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
AU2012219322A1 (en) 2011-02-17 2013-05-09 QRxPharma Ltd. Technology for preventing abuse of solid dosage forms
EP2683394B1 (en) 2011-03-09 2021-01-06 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
RU2573388C2 (ru) 2011-10-26 2016-01-20 Кемфарм Инк. Бензойная кислота, производные бензойной кислоты и конъюгаты гетероарилкарбоновой кислоты с гидроморфоном, пролекарства, способы получения и их применение
RU2673818C2 (ru) 2012-11-30 2018-11-30 Экьюра Фармасьютикалз, Инк. Саморегулируемое высвобождение фармацевтического ингредиента
JP6198495B2 (ja) 2013-07-12 2017-09-20 キヤノン株式会社 画像形成装置
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
EP3231420A1 (en) * 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
EP3210630A1 (en) 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions

Also Published As

Publication number Publication date
CL2018002463A1 (es) 2018-10-12
AU2017226880A1 (en) 2018-08-23
US11077196B2 (en) 2021-08-03
CA3016578A1 (en) 2017-09-08
EP3423034B1 (en) 2019-07-10
EP3423034A1 (en) 2019-01-09
US20190060471A1 (en) 2019-02-28
WO2017148927A1 (en) 2017-09-08
CN109069419A (zh) 2018-12-21
EP3560484A1 (en) 2019-10-30
EP3210596A1 (en) 2017-08-30
JP2019507173A (ja) 2019-03-14
ES2745579T3 (es) 2020-03-02
MX2018010436A (es) 2019-05-22

Similar Documents

Publication Publication Date Title
CL2016001131A1 (es) Uso de una combinación farmacéutica que comprende un compuesto inhibidor de mdm2 y uno o más agentes activos adicionales para el tratamiento del cáncer y composiciones farmacéuticas que comprenden dichas combinaciones.
BR112016023422A8 (pt) dispersão seca por spray, composição farmacêutica e seus usos, kit e comprimido
BR112015007083A2 (pt) inibidores de histona demetilases
CL2013001339A1 (es) Compuestos derivados heterociclicos condensados, con actividad antiviral; composicion farmaceutica que los comprende; y su uso para la prevencion o tratamiento de la infeccion de vih.
BR112018073329A2 (pt) combinação, composição farmacêutica, kit, método para tratar câncer, método para reduzir um nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade, método para reduzir metástase
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
BR112015015291A2 (pt) método e sistema para administrar o armazenamento de uma pluralidade de contêineres em área de armazenamento de carga que tem uma pluralidade de zonas
BR112017017457A2 (pt) composição hemostática e dispositivo hemostático (variantes)
BR112016024545A2 (pt) derivados de pirazolo pirimidina e seu uso como inibidores de malt1
BR112015020584A2 (pt) métodos para o tratamento de artrite psoriática usando apremilast
BR112016002233A2 (pt) composições de adoçante
BR112016010229A2 (pt) recipientes que têm um volume de produto e uma estrutura separada acoplada aos mesmos
BR112014008704A2 (pt) dispositivos de detecção de porca
BR112017009021A2 (pt) formulação farmacêutica de anticorpo anti-tnfa
BR112016011603A2 (pt) Formulação de combinação farmacêutica compreendendo amlodipina, losartana e rosuvastatina
BR112018006103A2 (pt) aplicador de precisão
BR112017016602A2 (pt) sistema e método de comunicação implementando um recipiente para um produto cosmético ou farmacêutico ou um vinho ou uma bebida alcoólica e dois dispositivos móveis de telecomunicação
CL2014003148A1 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.
BR112018067613A2 (pt) composição farmacêutica anti-abuso
CL2014002524A1 (es) Composicion farmaceutica que comprende un compuesto activo de formula 1, antagonista de ccr3, dos diluyentes, un aglutinante, un desintegrante y un lubricante; formas de dosificacion en capsula, comprimido o comprimido recubierto con pelicula.
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
BR112019024566A2 (pt) inibidores de pirazol magl
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
BR112018002520A2 (pt) Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements